Top-News
Pharmazeutika USA

Ionis Pharmaceuticals Inc News

Aktie
WKN:  A2ACMZ ISIN:  US4622221004 US-Symbol:  IONS
39,77 €
-0,42 €
-1,05%
03.05.24 16:49:05
Handeln Depot/Watchlist
Aktienanzahl *
145,75 Mio.
Marktkapitalisierung *
5,85 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 11.03.2024
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,51: ME9278

Ionis Pharmaceuticals Inc News

25.04.24 - PR Newswire
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Publishes 2023 Corporate Responsibility Report PR Newswire
23.04.24 - PR Newswire
Ionis to hold first quarter 2024 financial results webcast
Ionis to hold first quarter 2024 financial results webcast PR Newswire
07.04.24 - PR Newswire
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire
01.04.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
28.03.24 - PR Newswire
Ionis to hold olezarsen Phase 3 data webcast
Ionis to hold olezarsen Phase 3 data webcast PR Newswire
25.03.24 - PR Newswire
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire
13.03.24 - PR Newswire
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire
29.02.24 - PR Newswire
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR Newswire
28.02.24 - PR Newswire
Ionis to present at upcoming investor conferences
Ionis to present at upcoming investor conferences PR Newswire
21.02.24 - PR Newswire
Ionis reports fourth quarter and full year 2023 financial results
Ionis reports fourth quarter and full year 2023 financial results PR Newswire
15.02.24 - PR Newswire
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire
08.02.24 - PR Newswire
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-​mediated amyloid cardiomyopathy PR Newswire
07.02.24 - PR Newswire
Ionis to hold fourth quarter and full year 2023 financial results webcast
Ionis to hold fourth quarter and full year 2023 financial results webcast PR Newswire
22.01.24 - 4investors
Ionis Pharma will Zulassung in den USA für Donidalorsen beantragen
22.01.24 - PR Newswire
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR Newswire
08.01.24 - PR Newswire
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR Newswire
22.12.23 - 4investors
Ionis Pharmaceuticals: FDA-Zulassung für Wainua zur Behandlung von hATTR-PN
21.12.23 - PR Newswire
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-​mediated amyloidosis PR Newswire
20.12.23 - PR Newswire
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
18.12.23 - PR Newswire
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema PR Newswire

Newssuche

Videos

03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »